Abstract
Accumulation of inflammatory cells identifies atherosclerotic plaque at risk for rupture. Typically, activated immune cells occupy the rupture-prone areas of the atherosclerotic lesion. These cells are an appealing therapeutic target for novel strategies of plaque stabilization. Biologic consequences of plaque inflammation ultimately depend not only on the cellular players populating the lesion but also on triggers of immune activation originating from within the plaque or arriving from the circulation, and immune effector mechanisms that mediate cellular damage and plaque destabilization. Recent studies have provided insights into particular immune mechanisms in the atherosclerotic plaque that contribute to plaque vulnerability. This knowledge provides the basis for potential immunomodulatory therapies in cardiovascular disease. These therapeutic approaches can be classified as (1) immunomodulatory effects of existing therapies, (2) therapies targeting inflammatory triggers, and (3) agents inhibiting specific immune mechanisms.
Keywords: Inflammation, atherosclerosis, plaque, immune mechanisms, immunomodulatory therapies, cardiovascular disease
Current Pharmaceutical Design
Title: Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations
Volume: 13 Issue: 36
Author(s): A. Niessner, J. J. Goronzy and C. M. Weyand
Affiliation:
Keywords: Inflammation, atherosclerosis, plaque, immune mechanisms, immunomodulatory therapies, cardiovascular disease
Abstract: Accumulation of inflammatory cells identifies atherosclerotic plaque at risk for rupture. Typically, activated immune cells occupy the rupture-prone areas of the atherosclerotic lesion. These cells are an appealing therapeutic target for novel strategies of plaque stabilization. Biologic consequences of plaque inflammation ultimately depend not only on the cellular players populating the lesion but also on triggers of immune activation originating from within the plaque or arriving from the circulation, and immune effector mechanisms that mediate cellular damage and plaque destabilization. Recent studies have provided insights into particular immune mechanisms in the atherosclerotic plaque that contribute to plaque vulnerability. This knowledge provides the basis for potential immunomodulatory therapies in cardiovascular disease. These therapeutic approaches can be classified as (1) immunomodulatory effects of existing therapies, (2) therapies targeting inflammatory triggers, and (3) agents inhibiting specific immune mechanisms.
Export Options
About this article
Cite this article as:
Niessner A., Goronzy J. J. and Weyand M. C., Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations, Current Pharmaceutical Design 2007; 13 (36) . https://dx.doi.org/10.2174/138161207783018626
DOI https://dx.doi.org/10.2174/138161207783018626 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part I: (Patho)-Physiology, Rationale and Perspective on Pulse Pressure Amplification
Current Pharmaceutical Design Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Conjugation of Resveratrol with RGD and KGD Derivatives
Protein & Peptide Letters What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Current Vascular Pharmacology Secretory Production of Recombinant Proteins in Escherichia coli
Recent Patents on Biotechnology Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease
Current Pharmaceutical Design Supplements, Diets and Other Complementary and Alternative Interventions in Adolescent Mental Health
Adolescent Psychiatry Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Clozapine Safety, 40 Years Later
Current Drug Safety A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Long-Term Outcome of Cardio Respiratory Exercise Performance After Surgery
Current Respiratory Medicine Reviews Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling
Current Cardiology Reviews Endoplasmic Reticulum Stress as a Novel Therapeutic Target in Heart Diseases
Cardiovascular & Hematological Disorders-Drug Targets Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy